Currently Viewing
2018 FDA Advancements in Small Lymphocytic Leukemia
November 29, 2018 – Brielle Benyon
FDA Approves Xospata and Companion Diagnostic Test for Leukemia Treatment
November 28, 2018 – Brielle Benyon
FDA Approves First Biosimilar to Treat Non-Hodgkin Lymphoma
November 28, 2018 – Brielle Benyon
A Peek Inside CURE's Lung Cancer Special Issue
November 28, 2018 – Brielle Benyon and Katie Kosko
Immunotherapy May Mean No Chemotherapy for Some With Metastatic Head and Neck Cancer
November 27, 2018 – Katie Kosko
Standard Regimen Remains Superior in HPV-positive Oropharyngeal Carcinoma
November 27, 2018 – Kristie L. Kahl
FDA Approves Larotrectinib for NTRK-Positive Cancers
November 26, 2018 – Jason M. Broderick
Smartphone App Reduces Pain, Hospital Visits for Cancer Survivors
November 26, 2018 – Brielle Benyon
New Chemotherapy Combination Offers Improved Outcomes in Bladder Cancer
November 26, 2018 – Jessica Skarzynski

2018 FDA Advancements in Small Lymphocytic Leukemia

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.
BY Brielle Benyon
PUBLISHED November 29, 2018


The year 2018 was a busy one for the Food and Drug Administration (FDA) when it came to actions in the blood cancer space. There were three major advancements for the treatment of patients with small lymphocytic leukemia (SLL):
 
  • Venclexta plus Rituxan. This combination was approved in June for patients with SLL – as well as chronic lymphocytic leukemia (CLL) – who have already had at least one other form of treatment. The drugs are given intravenously, and the combination is approved to treat patients regardless of whether or not they have a 17p deletion.
  • Copiktra: In September, Copiktra (duvelisib) was granted FDA approval for patients with relapsed or refractory SLL or CLL who previously underwent two or more treatment options. Unlike Venclexta and Rituxan, Copiktra is given in pill form.
  • Imbruvica plus Gazyva. The drug combination Imbruvica (ibrutinib) plus Gazyva (obinutizumab) was granted priority review in October, meaning that the FDA will review and potentially approve the regimen in six months instead of the usual 10. If approved, the duo will be used to treat patients in the frontline setting.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Small Lymphocytic Lymphoma (SLL) CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In